Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0385-0434 First Human Dose in Healthy Subjects and Hypercholesterolaemia
NCT04058834Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2019
- Primary completion
- Apr 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0385-0434 in hypercholesterolemia (3 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment Emergent Adverse Events at Day 70. Started Aug 2019; status: completed.
02
Drugs
NNC0385-0434
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04058834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058834.